Bristol, families agree to $80M payment for those hurt in hep C trial

Bristol-Myers Squibb ($BMY) is close to clearing away the legal overhang of its failed hepatitis C program, having reached an agreement to pay $80 million to 15 patients who were harmed or died during its failed trial for experimental hepatitis C drug 094, The Wall Street Journal reports. The company and the patients or their families have tentatively reached a deal, but it still needs a final signoff. It is significantly more than the $40 million to $50 million BMS had hoped would be the top amount. The company killed the drug program after it was discovered that it was putting patients in danger. Story (sub. req.) | More

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.